Epstein–Barr virus and spontaneous lymphoblastoid cell lines: establishment, molecular characteristics, immune modulation, and therapeutic insight
Clinical and Experimental Immunology · 2025
DOI: 10.1093/cei/uxaf061 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Adekunle A Adeniran und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Immunobiology, Blizard Institute, Queen Mary University of London, London, United Kingdom. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, Epstein-Barr Virus Infections, B-Lymphocytes. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horne Family Foundation.
Abstract (Originalsprache)
Epstein–Barr virus (EBV) is a ubiquitous herpesvirus with well-established oncogenic potential, contributing to various malignancies and immune-mediated diseases. Its capacity to infect and immortalize B-cells forms the basis for the generation of lymphoblastoid cell lines (LCLs), which serve as vital models in immunology, virology, and translational research. While conventional LCLs are produced by exogenous EBV infection of peripheral blood mononuclear cells, spontaneous lymphoblastoid cell lines (S-LCLs) can emerge without deliberate viral inoculation, particularly in EBV-seropositive individuals. This review highlights multiple methodologies used to establish S-LCLs, including the use of cyclosporin A, CpG DNA, checkpoint kinase inhibitors, and cytokine modulation, and presents findings from diverse clinical contexts such as autoimmune diseases, post-transplant lymphoproliferative disorders, and cancer. We discuss the biological mechanisms underpinning EBV latency and reactivation, emphasizing the viral transcriptional programmes that drive B-cell transformation and persistence. Additionally, we explore how cytokines, particularly IL-10, support S-LCL survival, and how sodium butyrate and antiviral agents like acyclovir can influence EBV reactivation and replication. The review also considers the diagnostic and therapeutic relevance of LCLs, including their potential as antigen-presenting cells, vaccine platforms, and models for cellular immunotherapies such as CAR T-cells and virus-specific cytotoxic T lymphocytes. By evaluating the generation, molecular features, and immunological significance of S-LCLs, this review underscores their value in modelling EBV-driven disease and advancing novel therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Immunobiology, Blizard Institute, Queen Mary University of London, London, United Kingdom.
ORCID-Profile: Adekunle A Adeniran, Gavin Giovannoni, David Baker, Louisa K James
Förderung
- Horne Family Foundation
Zitieren
APA
Adeniran, A. A., Giovannoni, G., Baker, D., & James, L. K. (2025). Epstein–Barr virus and spontaneous lymphoblastoid cell lines: establishment, molecular characteristics, immune modulation, and therapeutic insight. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxaf061
Vancouver
Adeniran AA, Giovannoni G, Baker D, James LK. Epstein–Barr virus and spontaneous lymphoblastoid cell lines: establishment, molecular characteristics, immune modulation, and therapeutic insight. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxaf061
BibTeX
@article{Adeniran2025,
author = {Adeniran, Adekunle A and Giovannoni, Gavin and Baker, David and James, Louisa K},
title = {Epstein–Barr virus and spontaneous lymphoblastoid cell lines: establishment, molecular characteristics, immune modulation, and therapeutic insight},
journal = {Clinical and Experimental Immunology},
year = {2025},
doi = {10.1093/cei/uxaf061}
}
EUVIMED